Wed, Apr 10th 2024
MoonLake Immunotherapeutics teams up with Komodo Health in a landmark three-year tech partnership to transform the landscape of inflammatory skin and joint disease treatments.
MoonLake is at the forefront of developing innovative Nanobody® therapies for inflammatory diseases, aiming to significantly improve patient outcomes. Based in Zug, Switzerland.
Komodo Health offers real-world data insights through its platform, aimed at bridging gaps in healthcare and enhancing patient outcomes.
Their alliance to fight inflammatory skin and joint diseases was announced today in a press release. Leveraging Komodo’s comprehensive Healthcare Map, MoonLake aims to accelerate its Nanobody® therapy for diseases like hidradenitis suppurativa and psoriatic arthritis.
Psoriatic arthritis is a debilitating condition, affecting millions worldwide, characterised by joint pain and inflammation.
Hidradenitis suppurativa, a chronic skin condition, causes significant distress and challenges in treatment.
Nanobodies® represent the next wave of targeted therapies, offering disease intervention with their unique small structure and high specificity.
The U.S. sees over 240,000 new diagnoses of hidradenitis suppurativa annually, underscoring a vast treatment landscape.
MoonLake, poised to initiate phase 3 trials, will now use Komodo’s insights to navigate the market.
English 
German 
French 
Spanish 
Arabic